Novavax (NVAX – Research Report) received a Hold rating and price target from J.P. Morgan analyst Eric Joseph yesterday. The company’s shares closed yesterday at $14.40.
According to TipRanks, Joseph is a 4-star analyst with an average return of 4.8% and a 52.05% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Novavax, and TG Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novavax with a $13.00 average price target, representing a -9.72% downside. In a report released on May 13, TD Cowen also maintained a Hold rating on the stock with a $10.00 price target.
NVAX market cap is currently $2.02B and has a P/E ratio of -4.53.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NVAX in relation to earlier this year. Earlier this month, Filip Dubovsky, the President of NVAX sold 47,312.00 shares for a total of $657,636.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax (NVAX) Company Description:
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
